Kawasaki Disease Kawasaki disease, Children, Vasculitis, Coronary artery disease
Conditions
Sponsors
Hamada Hiromichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pediatric patients with a diagnosis of KD according to the Kawasaki Disease Diagnostic Criteria (the 6th revised edition)23) (the 6th revised edition prepared by Kawasaki Disease Research Committee, the Ministry of Health, Labour and Welfare, 2020). 2)Age of between 4 months and 15 years at the time of signing the informed consent form 3) Inclusion in the study within 9 days of disease onset (considering day 1 to be the day when the fever develops) 4)Informed consent form signed by a legal guardian
Exclusion criteria
Exclusion criteria: 1)Defervescence prior to enrollment 2)Suspicion that the symptoms may correspond to a disease other than KD (haemolytic streptococcal infection, EB virus infection, adenovirus infection Yersinia infection, measles, or Stevens-Johnson syndrome) 3)Initiation of IVIG treatment later than 9 days after disease onset 4)Having had treatment with tacrolimus (except external preparations), pitavastatin, rosuvastatin, bosentan, or aliskiren 5)History of hypersensitivity to CsA preparations, immunoglobulin preparations, or aspirin 6)Presence of an active bacterial infection: septicaemia, purulent meningitis, peritonitis or bacterial pneumonia 7)Treatment with other investigational drugs within 12 weeks of study commencement 8)Treatment with BCG vaccine or other live vaccine within 4 weeks of study commencement, or treatment with inactivated vaccine within 2 weeks of study commencement 9)Others: patients who are judged to be inappropriate for participants of the clinical study for safety reasons by the investigators or the sub-investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The relationship between genotypes of ITPKC SNVs (rs28493229; G/C) and the presence or absence of coronary artery lesions In addition, multivariate logistic analysis will be used with the following items as adjustment factors. hematocrit pretreatment coronary Z-score (right coronary artery, left main coronary artery, left anterior descending branch, Left circumflex branch) | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationship between the presence or absence of coronary artery lesions with a Z-score >= 2.5 or >= 3.0 within the study period (4 weeks after enrollment) and following items 1) genotypes of ITPKC and CASP3 SNVs (rs28493229; G/C and rs113420705; G/A) 2) hematological test values (including hematocrit) 3) biochemical test (including total bilirubin) 4) pretreatment blood cytokine/chemokine profile 5) Myl9 | — |
Contacts
Public ContactHaruna Ebisu
Chiba University Hospital
Outcome results
None listed